The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Tertiary Hyperparathyroidism

Autonomous Parathyroid Hyperfunction Following Long-Standing Secondary Hyperparathyroidism

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Endokrinoloji department. Book Appointment →

What is Tertiary Hyperparathyroidism?

Tertiary hyperparathyroidism (3HPT) is autonomous, persistent parathyroid hyperfunction following long-standing secondary hyperparathyroidism, characterized by hypercalcemia and inappropriately elevated PTH despite resolution of the original stimulus.

Most commonly develops after kidney transplantation in patients with prolonged dialysis-dependent secondary hyperparathyroidism (occurring in 25–50% of post-transplant patients), but also after correction of vitamin D deficiency, malabsorption, or renal recovery.

Pathophysiology involves diffuse hyperplasia progressing to nodular hyperplasia and monoclonal proliferation, with reduced calcium-sensing receptor (CaSR) and vitamin D receptor (VDR) expression, leading to autonomous PTH secretion.

Persistent hyperparathyroidism after transplantation contributes to graft dysfunction, hypercalciuria, nephrolithiasis, and bone loss; management balances PTH suppression with preservation of renal allograft function.

Symptoms

Hypercalcemia symptoms: fatigue, weakness, depression, cognitive disturbance, polyuria, polydipsia, constipation
Bone manifestations: bone pain, fractures from osteopenia or osteoporosis, less commonly osteitis fibrosa cystica or brown tumors
Renal manifestations: nephrolithiasis, nephrocalcinosis, declining estimated glomerular filtration rate (eGFR) of renal allograft
Vascular calcifications: arterial wall calcification with cardiovascular morbidity
Soft tissue calcifications and calciphylaxis (calcific uremic arteriolopathy) in advanced cases
Persistent or recurrent symptoms after kidney transplantation despite normalization of GFR
Many patients are asymptomatic with biochemical abnormalities discovered on routine post-transplant monitoring

Risk Factors

Long duration of dialysis-dependent secondary hyperparathyroidism (>3 years) prior to transplant
Severe pre-transplant secondary hyperparathyroidism with PTH levels >800 pg/mL
Marked parathyroid gland enlargement (especially nodular hyperplasia) on pre-transplant imaging
Inadequate medical control of secondary hyperparathyroidism on dialysis (calcimimetics, vitamin D analogues, phosphate binders)
Older age, longer time on dialysis, female sex, prior history of parathyroidectomy
Autoimmune polyglandular syndrome and MEN syndromes can predispose to similar autonomous hyperfunction
Functional autonomy can also occur after correction of severe vitamin D deficiency or osteomalacia

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Persistent hypercalcemia and elevated PTH 6–12 months after kidney transplantation
  • Symptomatic hypercalcemia, nephrolithiasis, declining graft function, or fragility fractures in transplant recipient
  • Pre-transplant patient with severe secondary hyperparathyroidism failing medical management
  • Suspected calciphylaxis with skin necrosis and severe pain
  • Asymptomatic but progressive bone density loss or vascular calcification on monitoring

Treatment Methods

01
Biochemical evaluation: serum calcium (corrected for albumin), ionized calcium, phosphate, intact PTH, 25-OH vitamin D, alkaline phosphatase, magnesium, creatinine and eGFR, 24-hour urine calcium
02
Imaging when surgery considered: neck ultrasonography, sestamibi parathyroid scintigraphy, 4D-CT, or PET-CT for localization of enlarged parathyroid glands
03
Bone density assessment: DEXA scan for osteoporosis evaluation; bone biopsy in selected cases for renal osteodystrophy classification
04
Conservative management: calcimimetic agents (cinacalcet 30–180 mg/day or etelcalcetide IV in dialysis patients) suppress PTH and lower calcium effectively; particularly useful for non-transplant or surgically high-risk patients
05
Active vitamin D analogues (calcitriol, paricalcitol, doxercalciferol) are limited in tertiary disease due to hypercalcemia risk; require careful monitoring
06
Phosphate binders (sevelamer, calcium-free phosphate binders preferred to limit calcium load) for residual hyperphosphatemia
07
Bisphosphonates or denosumab for fragility fractures and severe bone loss in selected patients (caution with denosumab discontinuation)
08
Parathyroidectomy: indications include persistent severe hypercalcemia (>11.5 mg/dL), persistent PTH elevation despite calcimimetic therapy, symptomatic hypercalcemia, declining graft function, severe bone disease, or calciphylaxis
09
Surgical options: subtotal parathyroidectomy (3.5 glands), total parathyroidectomy with autotransplantation, or focused parathyroidectomy in selected cases; intraoperative PTH monitoring and frozen section confirmation
10
Postoperative monitoring: hungry bone syndrome with hypocalcemia and hypophosphatemia requiring aggressive calcium and vitamin D supplementation, often for weeks to months
11
Long-term follow-up: serial PTH and calcium monitoring, kidney allograft function, bone density, cardiovascular risk assessment, and prevention of nephrolithiasis

Which Department to Visit?

You can visit our Endokrinoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Endokrinoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.